Prof. Thomas Decaens, M.D., Ph.D.

Prof. Thomas Decaens, M.D., Ph.D.


Dr Decaens is coordinator of a large nationwide prospective study focuses on the identification of new predictive factors of HCC recurrence after liver transplantation and is implicated in numerous clinical trials of targeted therapy of HCC. He lead a team devotes on liver cancer analysis at IAB, with special focus on immunomonitoring of patients treated for advanced HCC and on pre-clinical studies of new drugs based on an animal model of HCC in rats.

Grenoble-Alpes, France
Hepato-gastroenterology doctor
French / English

Work Experience

Professor of Medecine
University Grenoble-Alpes
Head of the Department of clinical research and innovation
CHU Grenoble Alpes
Head of Hepato-gastroenterology and digestive oncology department, head of the clinical research unit of the department of hepato-gastroenterology


Molecular basis of oncogenesis
University of Paris
Complementary medical degree
Medical Oncology
Thesis in molecular Carcinogenesis
University of Paris


GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition.
Therapeutic advances in chronic disease Read it here Idarubicin <i>vs</i> doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma.
World journal of gastroenterology Read it here Towards an integrative understanding of soil biodiversity.
Biological reviews of the Cambridge Philosophical Society Read it here

Professional Associations

Institute for Advance Biosciences (IAB) (INSERM U1209) Membre French liver tumor network Vice director “Fédération Française de Cancérologie Digestive (FFCD)” Member